Loading...
XWARRVU
Market cap223mUSD
Dec 20, Last price  
39.50PLN
1D
6.47%
1Q
-26.99%
Jan 2017
36.73%
IPO
619.49%
Name

Ryvu Therapeutics SA

Chart & Performance

D1W1MN
XWAR:RVU chart
P/E
—
P/S
19.49
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.09%
Rev. gr., 5y
-9.50%
Revenues
47m
+20.76%
8,846,6289,018,0589,419,84313,153,06828,864,75841,028,64148,133,12787,820,45977,205,57142,567,16315,414,30811,186,40238,804,00046,860,000
Net income
-92m
L+9.94%
00005,850,1266,269,8112,720,2116,406,932-106,320-35,998,690-31,687,587-77,534,706-83,782,000-92,112,000
CFO
-80m
L
000-694,940,040-4,902,078-16,429,766-6,280,11210,981,780-36,416,5860-10,635,891-57,867,88221,319,000-79,535,000

Profile

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
URL
https://ryvu.com/
IPO date
Jul 14, 2011
Employees
215
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
46,860
20.76%
38,804
246.89%
11,186
-27.43%
Cost of revenue
17,554
48,955
33,073
Unusual Expense (Income)
NOPBT
29,306
(10,151)
(21,887)
NOPBT Margin
62.54%
Operating Taxes
4,587
116
Tax Rate
NOPAT
29,306
(14,738)
(22,003)
Net income
(92,112)
9.94%
(83,782)
8.06%
(77,535)
144.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
250,284
237
BB yield
Debt
Debt current
541
1,903
2,751
Long-term debt
1,144
2,759
5,813
Deferred revenue
75,803
20,257
Other long-term liabilities
73,542
10,103
178
Net debt
(248,891)
(117,730)
(104,076)
Cash flow
Cash from operating activities
(79,535)
21,319
(57,868)
CAPEX
(8,579)
(9,287)
(11,982)
Cash from investing activities
(200,654)
690
8,055
Cash from financing activities
240,833
(2,455)
(3,170)
FCF
257,073
(228,877)
(22,023)
Balance
Cash
233,672
101,917
88,229
Long term investments
16,904
20,475
24,410
Excess cash
248,233
120,452
112,080
Stockholders' equity
(260,156)
99,445
191,347
Invested Capital
594,196
331,629
76,171
ROIC
6.33%
ROCE
8.77%
EV
Common stock shares outstanding
22,898
18,335
18,355
Price
Market cap
EV
EBITDA
40,277
2,749
(9,326)
EV/EBITDA
Interest
97
1,089
197
Interest/NOPBT
0.33%